Therapeutic nuclear medicine therapy for neuroendocrine neoplasm

This page provides information about new therapeutic nuclear medicine therapy Medicare services for patients with advanced prostate cancer, where prior treatment has failed.

Page last updated: 24 September 2025

From 1 November 2025, a new item for 177Lutetium-DOTA-somatostatin receptor agonist treatment will be listed on the Medicare Benefits Schedule for eligible patients with advanced neuroendocrine neoplasm.

A new whole-body 68Gallium-DOTA-octreotate SSTR positron emission tomography item will also be listed to determine a patient’s suitability to undergo treatment, monitor response to treatment, and assess the progression of recurrent or metastatic disease in patients with known somatostatin receptor positive neuroendocrine neoplasm.

Further information can be found in the Factsheet below:
Word version - Lutetium Dotatate for neuroendrocrine neoplasm .docxWord version - Lutetium Dotatate for neuroendrocrine neoplasm .docx
PDF version - Lutetium Dotatate for neuroendrocrine neoplasm.pdfPDF version - Lutetium Dotatate for neuroendrocrine neoplasm.pdf

In this section